Next Article in Journal
A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases
Previous Article in Journal
Persistent Ependymal Tumor Arising from an Immature Ovarian Teratoma: A Rare Case
Case Report

Concomitant Rare KRAS and BRAF Mutations in Lung Adenocarcinoma: A Case Report

1
Department of Public Health, University of Naples Federico II, 80131 Naples, Italy
2
Department of Oncology, A.O.R.N. Sant’Anna e San Sebastiano, 81100 Caserta, Italy
*
Author to whom correspondence should be addressed.
J. Mol. Pathol. 2020, 1(1), 36-42; https://doi.org/10.3390/jmp1010006
Received: 8 October 2020 / Revised: 30 October 2020 / Accepted: 2 November 2020 / Published: 3 November 2020
(This article belongs to the Special Issue Molecular Pathology of Lung Cancer)
In July 2020, an active smoker, 63-year old man was admitted to the oncology unit of A.O.R.N. Sant’Anna e San Sebastiano (Caserta, Italy). Chest radiology highlighted right pleural effusion. Total-body CT scanning revealed a solid lesion with lobulated contours in the apical segment of the upper right lobe. The patient’s oncologist requested a molecular assessment of EGFR, ALK, ROS1, BRAF, and KRAS, as well as an evaluation of PD-L1 expression level. To this end, we carried out NGS analysis, on DNA extracted from cytospins, by adopting a custom-designed NGS panel (SiRe®). Overall, no actionable mutations in the tested genes were identified. Conversely, concomitant BRAF exon 11 p.G469A and a KRAS exon 4 p.A146T mutations were detected. Owing to the limited data on the presence of KRAS exon 4 p.A146T point mutation in lung adenocarcinoma patients, a further molecular confirmatory analysis was carried out with a dedicated KRAS cartridge on a fully automated real time polymerase chain reaction. When DNA was extracted from the TTF-1 positive tumor cell slide, the same KRAS alteration was observed. Unfortunately, the patient died in August 2020 before having the chance to start any type of treatment. View Full-Text
Keywords: lung cancer; cytology; predictive molecular pathology; next generation sequencing; BRAF; KRAS lung cancer; cytology; predictive molecular pathology; next generation sequencing; BRAF; KRAS
Show Figures

Figure 1

MDPI and ACS Style

Iaccarino, A.; Pisapia, P.; De Felice, M.; Pepe, F.; Gragnano, G.; De Luca, C.; Ianniello, G.; Malapelle, U. Concomitant Rare KRAS and BRAF Mutations in Lung Adenocarcinoma: A Case Report. J. Mol. Pathol. 2020, 1, 36-42. https://doi.org/10.3390/jmp1010006

AMA Style

Iaccarino A, Pisapia P, De Felice M, Pepe F, Gragnano G, De Luca C, Ianniello G, Malapelle U. Concomitant Rare KRAS and BRAF Mutations in Lung Adenocarcinoma: A Case Report. Journal of Molecular Pathology. 2020; 1(1):36-42. https://doi.org/10.3390/jmp1010006

Chicago/Turabian Style

Iaccarino, Antonino, Pasquale Pisapia, Marco De Felice, Francesco Pepe, Gianluca Gragnano, Caterina De Luca, Giovanni Ianniello, and Umberto Malapelle. 2020. "Concomitant Rare KRAS and BRAF Mutations in Lung Adenocarcinoma: A Case Report" Journal of Molecular Pathology 1, no. 1: 36-42. https://doi.org/10.3390/jmp1010006

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop